WND By Jack Davis, The Western Journal 2/18/2022
Cite ongoing probes of side effectsDrug-maker Pfizer has backed away from efforts to secure emergency-use authorization in India for its COVID-19 vaccine.
India's Central Drugs Standard Control Organization said its experts did not support the vaccine because there are still investigations taking place into side effects that have been reported in other countries.
Indian officials had demanded Pfizer conduct a safety and efficacy study in India, according to Reuters.
“The firm presented its proposal for emergency use authorization of Covid-19 mRNA Vaccine BNT162b before the committee. The committee noted that incidents of palsy, anaphylaxis and other SAEs (serious adverse events) have been reported during post-marketing and the causality of the events with the vaccine is being investigated,” India’s ThePrint reported, citing minutes of the Feb. 3 meeting of the group’s experts.
The vaccines by Pfizer and Moderna have both been linked to an increased risk of myocarditis in some studies.
More:
https://www.wnd.com/2022/02/drug-regulator-bars-2-8-billion-people-pfizers-vaccine-cite-ongoing-probes-side-effects/